News
- Author:
- Susan London
Publish date: March 14, 2018
Atezolizumab had a marked survival benefit vs. chemotherapy in patients with TMB-high, PD-L1–positive urothelial tumors.
News
- Author:
- Susan London
Publish date: March 7, 2018
SAN FRANCISCO – Two new therapies that target VEGF signaling are efficacious and may expand the treatment for intermediate and advanced HCC.
News
- Author:
- Susan London
Publish date: February 13, 2018
SAN FRANCISCO - Metastasis-free survival was 36.6 months with enzalutamide and 14.7 months with placebo.
News
- Author:
- Susan London
Publish date: February 10, 2018
Primary results were comparable in the NRG/RTOG 0712 trial, but one regimen is more convenient.
News
- Author:
- Susan London
Publish date: February 9, 2018
SAN FRANCISCO - Trial enrollment was stopped early, after a median follow-up of 19.3 months, because of efficacy of chemotherapy.
News
- Author:
- Susan London
Publish date: February 8, 2018
SAN FRANCISCO – Adding docetaxel to first-line long-term hormone therapy for advanced prostate cancer, whether metastatic or not, improves quality ...
News
- Author:
- Susan London
Publish date: February 8, 2018
With a median follow-up of 8.4 months, the overall response rate was 16.3% and the median duration of response was 8.2 months.
News
- Author:
- Susan London
Publish date: February 7, 2018
With a median follow-up of 15 months, compared with sunitinib, the combination of atezolizumab and bevacizumab prolonged investigator-assessed prog...
News
- Author:
- Susan London
Publish date: February 7, 2018
The model contains six factors and predicts survival of patients given the immune checkpoint inhibitor atezolizumab in the postplatinum setting.
News
- Author:
- Susan London
Publish date: February 6, 2018
SAN FRANCISCO – Median overall survival was 17.4 months when regorafenib was given first and 11.6 months when cetuximab was given first in later-li...
News
- Author:
- Susan London
Publish date: February 6, 2018
The robot-assisted method works for patients with resectable esophageal cancer.
News
- Author:
- Susan London
Publish date: February 5, 2018
The androgen-receptor antagonist is highly effective for treating nonmetastatic castration-resistant prostate cancer.
News
- Author:
- Susan London
Publish date: January 29, 2018
Median progression-free survival was 5.85 months with ramucirumab and 5.55 months with placebo.
News
- Author:
- Susan London
Publish date: January 26, 2018
With median follow-up of 13.4 months, 55% of metastatic CRC patients had a response to the combination of nivolumab and ipilimumab in the nonrandom...
News
- Author:
- Susan London
Publish date: January 24, 2018
The CTC assay had an accuracy of 87.9% in the entire cohort of 620 colonoscopy patients, which included 327 patients with colorectal cancer of all ...
